Catalyst Dossier · compiled by CeliA 🧫
Theriva Biologics, Inc. (TOVX)
Pharmaceutical Preparations · market cap $12M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-08-01 (est.)
Phase 2
Pipeline
5
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Theriva Biologics, Inc. (TOVX) is a micro-cap pharmaceutical company with a market capitalization of approximately $12M and a stock price near $0.24. The company maintains a pipeline spanning gastrointestinal and oncology indications, including SYN-004, SYN-010, and a nab-paclitaxel program for pancreatic adenocarcinoma, all at Phase 2 stage. No upcoming catalysts are on the calendar and no recent catalysts have been disclosed, leaving the investment case largely speculative.
The catalyst path
- 2027-08-01 (est.)Phase 2 · VCN-01 oncolytic adenovirus (zabilugene almadenorepvec)imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) | Phase 2 | Pancreas Cancer, Metastatic |
| Period 1 - Treatment Sequence AB | Phase 2 | Healthy Volunteers |
| SYN-004 | Phase 2 | Healthy Volunteers With Ileostomy |
| SYN-010 | Phase 2 | Irritable Bowel Syndrome With Constipation (IBS-C) |
| SYN-010 21 mg | Phase 2 | Irritable Bowel Syndrome With Constipation (IBS-C) |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TOVX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.